...One Bay Area–based company, Omada Health, is making strides in addressing the prediabetes epidemic. The Omada Health program, Prevent, is an online version of a 2002 government-financed project sponsored by the National Institutes of Health called the Diabetes Prevention Program, which found that behavioral weight-loss programs can be more effective at combating diabetes than medication.
“Our 16-week online program helps people with prediabetes lose weight and adopt sustainable, healthy lifestyle changes,” says Sean Duffy, CEO of Omada Health. “In our program, we match people into groups of about 12 and bring them through the curriculum with a professionally trained health coach and all sorts of amazing digital tools, like a wireless-enabled scale, a Wi-Fi, or Bluetooth-enabled scale that wirelessly obtains your weight and measurements from your scale and syncs it, allowing you to visualize your weight loss online or on your smartphone. The goal is to create an environment where participants feel guided, supported, and put on a path toward better health.”
Duffy says that Prevent’s core model is to work with employers and insurers to cover the cost of the program, approximately $120 per month for the four-month course, since many employers and insurers are interested in new solutions to help their employees or members live healthier lives.
Read more: http://www.eastbaymedicalguide.com/East-Bay-Medical-Guide/Annual-2014/The-Prediabetes-Wake-up-Call/
ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine
San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign. These patents enhance the Company’s already strong proprietary position for its VC-01™ combination product as well as other applications of its broad technology platform.
AtheroMed announces results of the EASE study evaluating the Phoenix Atherectomy System in treating peripheral artery disease
MENLO PARK, CA – October 21, 2013 – AtheroMed, a developer of innovative catheter technologies for treating peripheral artery disease (PAD), announced results from its Endovascular Atherectomy Safety and Effectiveness (EASE) study during a Late Breaking Clinical Trials Session at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas. Stephen Williams, MD, Director of the Vascular Medicine Center at Johns Hopkins University, presented the results of the study, which demonstrate the safety and effectiveness of the Phoenix Atherectomy System in treating PAD.
REDWOOD CITY, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has granted OncoMed its first U.S. patent on its MAbTrap™ antibody display technology, one of the company's novel antibody platform technologies. OncoMed's MAbTrap™ technology enables the rapid identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity. OncoMed has used the patented technology to identify and/or optimize novel antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.
Via CNN Money:
FORTUNE -- A few weeks ago I wrote a column for the magazine about how most health apps don't work very well, aren't reaching those most in need, and -- besides -- counter to all claims that technology will save health care, several proven solutions involve real people, interacting with other real people, in real life. My goal was to call B.S. on what I find to be an all-too-pervasive Valley-ism: that smartphone software that tracks steps or helps photograph food or replaces your doctors visit will revolutionize medicine and change the world. No. For the most part, health apps are selling to the least needy but most willing buyers: rich people who care about being healthy. My colleague Dan Primack, who is out in the Bay Area this week, calls it "a particularly insular narcissism" in Silicon Valley, which seems exactly right.
AtheroMed announces completion of patient enrollment in the EASE study evaluating the Phoenix Atherectomy System in treating PAD
MENLO PARK, CA – October 2, 2013 – AtheroMed, a developer of innovative technologies for treating peripheral artery disease (PAD), announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances (VIVA) conference in Las Vegas.
MALVERN, Pa., August 19, 2013 – TetraLogic Pharmaceuticals, a biopharmaceutical company
Santa Clara, CA, July 24, 2013 — ProteinSimple today introduced the FluorChem R system as the next member of the FluorChem product family. The FluorChem R system is a fully integrated, multimode gel and Western blot imager with chemiluminescent, fluorescent, and infrared detection capabilities.
ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company’s largest existing investors – Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).
Judy Twist shares with Lisa her success with the program Prevent.